Waiv
AI-powered precision testing for patient care
About
Waiv is a Paris-based health tech startup spun out of Owkin (formerly Owkin Dx), established around 2024. It leverages AI to deliver precision diagnostics focused primarily on cancer care, enabling better identification of patients both in clinics and clinical trials. The company’s AI-driven platform aims to transform patient care by improving diagnostic accuracy and enabling personalized treatment strategies. Waiv operates by providing healthcare providers and researchers with advanced AI-powered tools to support clinical decision-making and accelerate drug development processes.
Products
-
AI-powered precision testing
— AI-driven tests to identify and stratify patients in clinics and clinical trials, improving patient care.
Customer sectors: oncology clinics, clinical researchers, drug developers
-
RlapsRisk BC risk profiling
— Prognostic risk profiling tool predicting patient outcomes in breast cancer care.
Customer sectors: oncologists, clinical trial teams, cancer researchers
-
Destra deployment platform
— Platform to deploy AI-powered precision tests in clinical and research environments.
Customer sectors: healthcare IT, clinical operations, pharma companies
-
MSIntuit collaboration
— Collaboration platform with MSD to advance translational medical AI in drug development.
Customer sectors: pharmaceutical partners, drug developers
-
Patient Validation ecosystem
— Integrated framework to validate AI models using real-world patient data and organoid testing.
Customer sectors: clinical researchers, pharma companies, regulatory affairs
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Waiv — available to members.
